-
SIRT1, Mitochondrial Biogenesis, and Prion Toxicity
2026-09-02
Zhao et al. identify a SIRT1–PGC-1α–TFAM axis that links mitochondrial biogenesis to protection from PrP106–126-induced damage in N2a neuroblastoma cells. The study places resveratrol-mediated SIRT1 activation within a mechanism-resolved framework for studying mitochondrial dysfunction and apoptosis in prion disease models.
-
Obeticholic Acid: FXR Assay Guide
2026-09-01
This scenario-based guide explains how Obeticholic Acid (6alpha-ethyl-chenodeoxycholic acid, 6-ECDCA, INT-747), SKU B4888, can improve the design and interpretation of FXR-focused viability, proliferation, and cytotoxicity experiments. It covers solvent compatibility, concentration selection, orthogonal readouts, liver fibrosis context, and practical vendor-selection criteria.
-
Tomivosertib and Human DRG Neuron Ectopic Activity
2026-08-31
The reference study demonstrates that MNK inhibition with tomivosertib rapidly and reversibly suppresses spontaneous activity in cultured human DRG neurons obtained from patients with radiculopathy. Its combination of electrophysiology and eIF4E phosphorylation analysis provides translational evidence that MNK signaling contributes to ectopic nociceptor excitability, while also defining important limits for clinical interpretation.
-
FUS–PARP1 Phase Separation: Cation and PAR Control
2026-08-31
Sukhanova and colleagues show that FUS assembly with PARylated PARP1 depends on both the ionic environment and the architecture of the attached poly(ADP-ribose) chain. Their reconstituted biophysical approach distinguishes cation-dependent condensation from a form driven by hyperbranched PAR, offering a mechanistic framework for interpreting PAR-associated DNA repair condensates.
-
Mitoxantrone: A Three-Layer Assay Strategy
2026-08-30
Mitoxantrone is more than a DNA-damage reagent: it can connect target engagement, intracellular exposure, and apoptosis in a single research framework. This article explains how the marein–ABCG2 study improves assay interpretation without overstating transporter reversal or antiviral evidence.
-
Rucaparib: A Causal Framework for DNA-Damage Assays
2026-08-29
Rucaparib (AG-014699) is a potent PARP1 inhibitor for dissecting repair-dependent radiosensitization. This article presents an orthogonal assay framework that separates established DNA damage mechanisms from emerging RNA Pol II–linked apoptosis hypotheses.
-
Biotin (Vitamin B7) for Motor-Protein Assays
2026-08-28
Use Biotin (Vitamin B7) as a controlled metabolic supplement, avidin-binding reference, and quality-control component in protein-labeling workflows. Applied to BicD–MAP7–kinesin experiments, it helps separate motor activation from surface capture and highlights when free biotin should—and should not—be added.
-
Cycloheximide in Ferroptosis Mechanism Studies
2026-08-28
Cycloheximide provides a controlled way to test how translation and protein stability shape ferroptosis in clear cell renal cell carcinoma. This article translates OTUD3–SLC7A11 findings into better protein turnover study design while separating established evidence from practical extrapolation.
-
MMAE and Tumor Plasticity: A Mechanistic Guide
2026-08-28
Monomethyl auristatin E (MMAE) is more than a high-potency cytotoxic payload: its activity can expose how tumor cell state influences antibody-drug conjugate response. This guide connects MMAE assay design with mechanistic insights from EBV-associated nasopharyngeal carcinoma research while clearly separating established evidence from translational hypotheses.
-
Hoechst 33342 for Fibroblast Aging Assays
2026-08-27
Use Hoechst 33342 as a low-complexity nuclear anchor for live-cell imaging, fixed-cell analysis, and flow cytometry in dermal fibroblast aging studies. Its membrane permeability supports live-cell workflows, while consistent nuclear segmentation strengthens mitochondrial, senescence, and cell-count readouts.
-
Cathepsin B inhibitor CA-074: Workflow Guide
2026-08-26
CA-074 provides a selective biochemical tool for testing cathepsin B involvement in proteolysis, cancer metastasis, neurotoxicity, and immune response modulation. This dossier-based guide covers stock preparation, controls, and interpretation; it should not be used as a substitute for independently matched paper validation or as proof of cathepsin B dependence in every cell type.
-
Rucaparib (AG-014699) DNA Repair Workflow
2026-08-26
Rucaparib (AG-014699) offers a practical way to interrogate PARP1-dependent DNA repair, radiosensitization, and repair-deficient cancer models. This research workflow combines formulation guidance, dose-response design, DNA damage imaging, transporter-aware controls, and assay interpretation informed by recent Pol II degradation findings.
-
Pam3CSK4 and the Neuro-Immune Inflammation Axis
2026-08-26
A translational framework for using Pam3CSK4 as a defined TLR1/2 agonist to connect innate immune activation with emerging somato-autonomic mechanisms of inflammation control.
-
DiR for Longitudinal MSC Neurobiology
2026-08-25
DiR (DiIC 18 (7)) enables near-infrared tracking of mesenchymal stromal cells while preserving the distinction between cell localization and therapeutic mechanism. This guide translates recent perioperative neurocognitive disorder findings into a rigorous, longitudinal imaging strategy.
-
Nanoparticle Uptake by Human Cornea Cells
2026-08-24
The 2024 ACS Biomaterials Science & Engineering study by Azadi and David separates nanoparticle size and surface chemistry as determinants of uptake by human corneal epithelial cells. Its in vitro mucosal model and inhibitor-based analysis indicate that energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated uptake, dominates across the tested PLGA nanoparticle designs.